These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22569034)

  • 1. A bit of antithymocyte globulin can take you a long way!
    Mohty M
    Bone Marrow Transplant; 2012 May; 47(5):617-8. PubMed ID: 22569034
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
    Lee KH; Choi SJ; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Yun SC; Joo YD; Lee WS; Kang MJ; Kim H; Park JH; Bae SH; Ryoo HM; Kim MK; Hyun MS
    Am J Hematol; 2011 May; 86(5):399-405. PubMed ID: 21523798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.
    Chang YJ; Wang Y; Mo XD; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Chen Y; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Cancer; 2017 Aug; 123(15):2881-2892. PubMed ID: 28301690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
    Devillier R; Crocchiolo R; Castagna L; Fürst S; El Cheikh J; Faucher C; Prebet T; Etienne A; Chabannon C; Vey N; Esterni B; Blaise D
    Bone Marrow Transplant; 2012 May; 47(5):639-45. PubMed ID: 22307016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unrelated stem cell transplantation after a reduced intensity conditioning regimen containing high-dose thymoglobulin leads to controllable graft-versus-host disease.
    Lacerda JF; Martins C; Lourenço F; Carmo JA; Juncal C; Oliveira JJ; Lacerda JM
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):494-7. PubMed ID: 17382257
    [No Abstract]   [Full Text] [Related]  

  • 6. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
    Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithymocyte globulin in the conditioning regimen: why not?
    Bacigalupo A
    Biol Blood Marrow Transplant; 2014 May; 20(5):597-8. PubMed ID: 24641827
    [No Abstract]   [Full Text] [Related]  

  • 8. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Duléry R; Mohty M; Duhamel A; Robin M; Beguin Y; Michallet M; Vigouroux S; Lioure B; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Daguindau E; Ceballos P; Clément L; Dauriac C; Maillard N; Legrand F; Cornillon J; Guillerm G; François S; Lapusan S; Chevallier P; Damaj G; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2014 May; 20(5):646-54. PubMed ID: 24462982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
    Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Umbilical Cord Blood Transplantation without Antithymocyte Globulin Results in Similar Survival but Better Quality of Life Compared with Unrelated Peripheral Blood Stem Cell Transplantation for the Treatment of Acute Leukemia-A Retrospective Study in China.
    Tong J; Xuan L; Sun Y; Huang D; Liu H; Zheng C; Zhu X; Tang B; Song K; Zhang X; Zhang L; Yao W; Lin D; Liu Q; Sun Z
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1541-1548. PubMed ID: 28499936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antithymocyte globulin as conditioning regimen for bone marrow transplantation].
    Kobayashi R; Kumon K; Watanabe N; Iguchi A; Cho Y; Yoshida M; Arioka H; Naito H; Shikano T; Ishikawa Y
    Rinsho Ketsueki; 1997 Nov; 38(11):1183-8. PubMed ID: 9423335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
    Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The comparison of fludarabine or antithymocyte globulin based non-myeloablative conditioning regimen for haematologic diseases with graft-versus-host disease].
    Li QS; Zhuang XY; Mao P
    Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):555-7. PubMed ID: 22338182
    [No Abstract]   [Full Text] [Related]  

  • 15. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Ravinet A; Cabrespine A; Socié G; Milpied N; Yakoub Agha I; Nguyen S; Michallet M; Menard AL; Maillard N; Mohty M; Suarez F; Huynh A; Marchand T; Deteix C; Cassuto JP; Maury S; Chevallier P; Reman O; Peffault de Latour R; Bay JO
    Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanter?
    Hamadani M
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):292-4. PubMed ID: 24394802
    [No Abstract]   [Full Text] [Related]  

  • 19. Favourable response to antithymocyte globulin therapy in resistant acute graft-versus-host disease.
    Tagliabue A; Corti P; Viganò E; Bonanomi S; Uderzo C
    Bone Marrow Transplant; 2005 Sep; 36(5):459. PubMed ID: 15980883
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
    Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
    Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.